Alcon Acquired by Novartis
On December 15, 2010, Novartis (NYSE: NVS) agreed to acquire the remaining shares of Alcon, Inc. (NYSE: ACL) it doesn't currently own for $168 per share.
The merger consideration will be comprised of a combination of Novartis shares and, if necessary, a cash contingent value amount to result in a total value of $168 per share.
Upon completion of the merger, Alcon will become the second largest division within Novartis. CIBA VISION and select Novartis ophthalmic medicines will be integrated into Alcon, forming an organization with more than $8.7 billion in sales covering over 70 percent of the eye care segment.
The merger consideration will be comprised of a combination of Novartis shares and, if necessary, a cash contingent value amount to result in a total value of $168 per share.
Upon completion of the merger, Alcon will become the second largest division within Novartis. CIBA VISION and select Novartis ophthalmic medicines will be integrated into Alcon, forming an organization with more than $8.7 billion in sales covering over 70 percent of the eye care segment.
View Older Stories View More Recent Stories
-
Rapidly Growing Patent Law Firm in Spokane Adds Pharmaceutical Division with New Dallas-Based Partner
-
Open Lending Appoints Kevin Filan as Senior Vice President of Marketing
-
Mallinckrodt (MNK) Appoints Peter Richardson as Chief Scientific Officer
-
Mallinckrodt Announces Appointment of Dr. Peter Richardson, MRCP, as Chief Scientific Officer
-
ADC Therapeutics SA (ADCT) Appoints Jose Carmona as CFO
-
ADC Therapeutics Appoints Jose Carmona as Chief Financial Officer
-
Alcon Completes Acquisition of Aerie Pharmaceuticals, Inc., Strengthening Company’s Ophthalmic Pharmaceutical Business
-
Alcon Completes Acquisition of Aerie Pharmaceuticals, Inc., Strengthening Company’s Ophthalmic Pharmaceutical Business
-
Novartis weighs sale of ophthalmology, respiratory units - Bloomberg
-
Dopavision Appoints Dr. Dirk Sauer as Chair of the Company's Advisory Board
-
Dopavision Appoints Dr. Dirk Sauer as Chair of the Company's Advisory Board
-
Open Lending Appoints Simona Fillarini as Chief Human Resources Officer, Thinh Nguyen as Chief Information Officer and Jill Tyson as Senior Vice President of Operations
-
Alcon to Celebrate 75 Years of Brilliance and Showcase Contact Lens Innovations at #Academy22
-
SHORELINE BIOSCIENCES ANNOUNCES APPOINTMENT OF CELL THERAPY MANUFACTURING VETERAN CHARLES CALDERARO III AS CHIEF TECHNICAL OFFICER
-
MAPS PBC Elects Jeff George as Chairman of the Board of Directors
-
Novartis to prioritise U.S. market, unfazed by drug pricing pushback
-
Eyenovia Chairman Dr. Sean Ianchulev: The Making Of An iDoctor - Immigrant, Innovator, Inventor
-
Eyenovia Chairman Dr. Sean Ianchulev: The Making Of An iDoctor - Immigrant, Innovator, Inventor
-
Analysis-Novartis CEO may struggle to rally investors to Sandoz spin-off
-
Analysis-Novartis CEO may struggle to rally investors to Sandoz spin-off
-
Analysis-Novartis CEO may struggle to rally investors to Sandoz spin-off
-
Analysis-Novartis CEO may struggle to rally investors to Sandoz spin-off
-
Analysis-Novartis CEO may struggle to rally investors to Sandoz spin-off
-
Analysis-Novartis CEO may struggle to rally investors to Sandoz spin-off
-
Analysis-Novartis CEO may struggle to rally investors to Sandoz spin-off
-
Analysis-Novartis CEO may struggle to rally investors to Sandoz spin-off
-
Analysis-Novartis CEO may struggle to rally investors to Sandoz spin-off
-
Novartis to spin off generics business Sandoz next year
-
Alcon (ALC) Acquires Aerie Pharmaceuticals (AERI) for $15.25/sh or $770M
-
Alcon to Acquire Aerie Pharmaceuticals, Inc., Enhancing its Ophthalmic Pharmaceutical Portfolio
-
Alcon to Acquire Aerie Pharmaceuticals, Inc., Enhancing its Ophthalmic Pharmaceutical Portfolio
-
Emery Pharma Announces New Biologics Analytical Division
-
The Galien Foundation Announces 2022 Prix Galien USA Nominees in "Best Biotechnology Product," "Best Pharmaceutical Agent" and "Best Medical Technology" Categories
-
Xequel Bio Expands Leadership Team with Appointments of Dr. Michael J. Brubaker as Chief Scientific Officer and Tony C. Tipton as Chief Operating Officer
-
Nicox Extraordinary General Meeting of July 11, 2022
-
Immunocore (IMCR) Appoints Siddharth (Sid) Kaul to its Board
-
Immunocore Appoints Siddharth Kaul to its Board of Directors
-
Immunocore Appoints Siddharth Kaul to its Board of Directors
-
MAPS Appoints Jeff George and Dan Grossman to MAPS PBC Board of Directors
-
Football Star Cooper Kupp Encourages Eye Allergy Sufferers to Find the Right Tool for the Job with Pataday
-
EQT pushes back Galderma IPO plans amid market turmoil - sources
-
The Bloc Hires Christian Bauman as Chief Creative Officer
-
Opthea (OPT) Appoints Quinton Oswald and Susan Orr to its Board
-
Opthea strengthens its Board of Directors
-
Opthea strengthens its Board of Directors
-
Nanoscope Therapeutics Appoints Pharma Industry Veteran Aaron Osborne, MBBS, as Chief Medical Officer and Chief Development Officer
